Reference : De novo mutations in hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS).
Scientific journals : Article
Life sciences : Genetics & genetic processes
http://hdl.handle.net/10993/17289
De novo mutations in hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS).
English
Karle, Kathrin N. [> >]
Biskup, Saskia [> >]
Schule, Rebecca [> >]
Schweitzer, Katherine J. [> >]
Krüger, Rejko mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
Bauer, Peter [> >]
Bender, Benjamin [> >]
Nagele, Thomas [> >]
Schols, Ludger [> >]
2013
Neurology
81
23
2039-44
Yes (verified by ORBilu)
0028-3878
1526-632X
United States
[en] Adult ; Female ; Humans ; Leukoencephalopathies/diagnosis/genetics ; Male ; Middle Aged ; Mutation/genetics ; Young Adult
[en] OBJECTIVE: Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) is caused by autosomal-dominantly inherited mutations in the colony stimulating factor 1 receptor (CSF1R) gene, and is clinically characterized by a progressive cognitive and motor decline leading to death within several years. METHODS: In a continuous series of 25 patients with adult-onset leukoencephalopathy of unknown cause, we genetically confirmed HDLS in 6 families. Affected and nonaffected individuals were examined clinically and by brain MRI studies. RESULTS: HDLS presented as prominent dementia and apraxia, often with extrapyramidal and pyramidal signs, rarely with ataxia. White matter MRI changes were detectable early in the disease course. Family history was negative in 4 of 6 index patients. In 2 of 6 index patients, we could confirm the occurrence of de novo mutations in the CSF1R gene. One family showed possible incomplete penetrance: the 69-year-old father of the index patient carried a CSF1R mutation but was clinically unaffected. In one family, the parents were apparently unaffected and not available for genetic testing. CONCLUSIONS: Typical clinical phenotype and early brain MRI alterations can help to guide the diagnosis of HDLS. Because we confirmed de novo mutations in one-third of patients with CSF1R mutations, this diagnosis should be considered even in the absence of a family history. Furthermore, we present evidence for reduced penetrance of a CSF1R mutation. These results have substantial impact for genetic counseling of asymptomatic individuals at risk and should foster research into disease-modifying factors.
Luxembourg Centre for Systems Biomedicine (LCSB): Clinical & Experimental Neuroscience (Krüger Group)
http://hdl.handle.net/10993/17289

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Limited access
Neurology-2013-Karle-2039-44.pdfPublisher postprint359.19 kBRequest a copy

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.